Akums Drugs & Pharmaceuticals Ltd. on Thursday announced that it has entered into an in-licensing agreement with Caregen Co., Ltd., a biotechnology player based in South Korea.
According to the company’s statement, this strategic alliance marks a significant step in introducing specialty nutraceuticals, Pharmaceuticals , differentiated topical and injectable cosmeceuticals—including advanced Skinceuticals and Hairceuticals—tailored to meet the unique needs of Indian consumers.
The collaboration brings together Caregen’s global expertise in peptides, growth factors, and advanced formulations with Akums’ manufacturing capabilities and expansive market reach. By uniting their strengths, the partnership aims to deliver science-backed, innovative solutions aligned with the rising consumer focus on health, beauty, and wellness in India, it stated.
According to the company, this agreement sets the stage for the launch of an array of innovative products, including topical solutions for skin and hair care, injectable products targeting deeper rejuvenation and repair, and premium nutraceuticals designed for holistic wellness. These offerings leverage Caregen’s proprietary peptide-based technologies and Akums’ ability to scale production and ensure quality, enabling the introduction of global-standard products to Indian markets.
India’s cosmeceutical and nutraceutical sectors are experiencing rapid growth, driven by increasing consumer awareness of health and wellness. This partnership positions Akums and Caregen as leaders in addressing the evolving needs of these markets. The products will cater to India’s diverse demographics, unique climatic conditions, and varied lifestyles, delivering customized solutions that resonate with local consumers.
“We are delighted to partner with Caregen in this transformative journey. Together, we will introduce innovative and impactful products that empower individuals to look and feel their best. This partnership highlights Akums’ commitment to setting new benchmarks in healthcare and beauty,” Sanjeev Jain, Managing Director of Akums he said.
Dr. Chung Yong-Ji, CEO of Caregen, echoed the sentiment: “India represents an exciting and dynamic market with tremendous potential. We believe integrating pharmaceutical solutions alongside our nutraceutical and cosmeceutical offerings could significantly enhance the value we deliver to our consumers. This expansion aligns closely with both companies’ strategic goals of diversifying and strengthening our product portfolios in the healthcare sector.”
The initiative aligns with India’s ‘Make in India’ vision, as these global-standard products will be manufactured locally, supporting economic growth and reducing reliance on imports, the company stated.